Personalized Medicine in Brief: Vol. 10 (Spring 2018)

The Spring 2018 edition of PMC's newsletter, Personalized Medicine in Brief, includes original essays, issue briefs and a book review that together demonstrate how the personalized medicine landscape is rapidly evolving.

Among other topics, the newsletter covers the U.S. Food and Drug Administration (FDA)'s decision to bolster the trend toward direct-to-consumer genetic testing on March 6, 2018, by approving an at-home personalized test marketed by 23andMe that provides information about a patient's personal risk of developing breast and ovarian cancer (page 10).

It also documents the U.S. Centers for Medicare and Medicaid Services (CMS)' decision to cover next-generation sequencing (NGS) tests nationwide for patients with advanced cancer and analyzes CMS' approach to implementing the Protecting Access to Medicare Act (PAMA) (page 8; page 12).

Previous Newsletter Issues

Join Today

PMC members shape and advance the future of personalized medicine.
Join Today